2002 : Société d’Histoire de Bruebach

Bruebach est un village de la banlieue sud de Mulhouse. Il comptait en 1846 : 672 habitants ; en 1962 : 359. Mais depuis il s’est considérablement développé. En 1999 : 953 habitants ; actuellement environ 1030. Il fait partie de la « Communauté des Communes des collines » (CO.CO.CO). Création de la société L’assemblée générale constitutive s’est réunie le lundi 17 juin 2002. Vingt-deux membres fondateurs étaient présents. Siège provisoire : 27 rue de Flaxlanden, 68440 Bruebach. Nombre d’adhér..

NOACs added to WHO’s essential medicines list: recommendations for future policy actions

The introduction of non-vitamin K antagonists oral anticoagulants, a class of medicines which includes dabigatran, apixaban, edoxaban and rivaroxaban, has resulted in improvements in the safety and efficacy of non valvular atrial fibrillation treatment for stroke prevention, with significant reductions in stroke, intracranial haemorrhage, and mortality. For these reasons, a team of World Heart Federation Emerging Leaders led efforts to add non-vitamin K antagonists oral anticoagulants to the World Health Organization’s Model List of Essential Medicines in 2019. Following the inclusion of this class of medicines in the Essential Medicines List, this editorial proposes several recommendations to improve the accessibility, affordability and acceptability of non-vitamin K oral anticoagulants, especially in low- and middle-income settings, in order to successfully manage non-valvular atrial fibrillation and to lower the risk of stroke

WHF Position Statement on COVID Vaccination

The current COVID-19 pandemic has challenged health systems and communities globally. As such, several countries have embarked on national COVID-19 vaccination programmes in order to curb spread of the disease. However, at present, there isn't yet enough dosages to enable vaccination of the general population. Different vaccine prioritization strategies are thus being implemented in different communities in order to permit for a systematic vaccination of individuals. Here, on behalf of the World Heart Federation, we emphasize the need for individuals with Cardiovascular disease to be prioritized in national vaccine prioritization programmes as these are high risk individuals